Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cirmtuzumab and Ibrutinib in B-Cell Lymphoid Malignancies
NCT03088878Phase 2Completed
- Sponsor
- Oncternal Therapeutics
- Start
- Jan 2018
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cirmtuzumab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), sponsored by Oncternal Therapeutics. Started Jan 2018; status: completed.
02
Drugs
cirmtuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)mantle cell lymphoma (MCL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT03088878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03088878.